Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi

Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi

AVIV, Israel, May 10, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company

focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response

rate, and slow tumor progression, today announced that it has received a notice of allowance from the U.S. Patent and Trademark

Office for its Patent Application 16/008,538, "Celecoxib and Amlodipine formulation and methods of making the same,"

covering the proprietary formulation of Consensi , Kitov's commercial-stage product for the simultaneous treatment

of osteoarthritis pain and hypertension. The patent application was filed jointly with Dexcel Pharma Ltd., Kitov's manufacturing

partner for Consensi , which has provided Kitov with perpetual, royalty-free, license rights for the use of the patent in

connection with distribution of Consensi in the U.S.

are pleased with this development. The new patent will further strengthen Kitov's proprietary position and long-term market exclusivity

for Consensi in the U.S., together with the existing Orange Book listed patent. We look forward to the commercial launch

in the U.S. by our commercialization partner, Coeptis Pharmaceuticals, which is planned for the fourth quarter of 2019."

stated Kitov CEO, Isaac Israel.

Mehalick, Co-founder & Executive Vice President of Coeptis, said, "Consensi will substantially improve treatment

for patients living with two highly prevalent chronic conditions, delivering improved clinical outcomes and enhanced economics

for healthcare providers. We expect to have it widely available soon to the millions of Americans who can benefit from this combination

Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative pharmaceutical drug development company. Leveraging deep regulatory

and clinical trial expertise, Kitov's veteran team of healthcare and business professionals maintains a proven track record

in streamlined end-to-end drug development and approval. Kitov's combination drug, Consensi , treating osteoarthritis

pain and hypertension simultaneously, was approved by the FDA for marketing in the U.S and is partnered in the U.S, China and

South Korea. In addition, Kitov's NT219, is a novel patented small molecule designed to overcome cancer drug resistance

that is currently in pre-clinical development. Kitov is under contract to acquire 100% of FameWave Ltd. which owns CM-24, a humanized

monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), an immune checkpoint

protein belonging to the Human CEA (Carcino-Embryonic Antigen) protein family. CM-24 is being developed for multiple oncological

indications according to the expression pattern of its target protein. Following the recent receipt of the approval of Kitov's

shareholders for the acquisition of FameWave, and the finalization of a clinical collaboration agreement between FameWave and

Bristol Myers Squibb (NYSE:BMY) for their planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with nivolumab

(Opdivo ), a PD-1 inhibitor, the acquisition is expected to close during the third quarter of 2019, subject to fulfillment

of certain additional closing conditions.

lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver

rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives. For more information

on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.

Statements and Kitov's Safe Harbor Statement

statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements

within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking

statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words

such as "believe", "expect", "intend", "plan", "may", "should",

"could", "might", "seek", "target", "will", "project",

"forecast", "continue" or "anticipate" or their negatives or variations of these words or

other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place

undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements

reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,

involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause

our actual results, performance or achievements to be significantly different from any future results, performance or achievements

expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include,

among others, risks relating to: the manner in which the parties to the transaction for the acquisition of FameWave by Kitov plan

to effect the transaction; the expected benefits, synergies and costs of the transaction; management plans relating to the transaction;

the expected timing of the completion of the transaction; the parties' ability to complete the transaction considering the

various closing conditions; the plans, strategies and objectives of management for future operations; product development for

NT219 and CM-24; the potential future financial impact of the transaction; and any assumptions underlying any of the foregoing;

the process by which early stage products such as CM-24 could potentially lead to an approved product is long and subject to highly

significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization

involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical

products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical

trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty

in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of

the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment

and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market

reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products;

patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products;

our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference

or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure

to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an investigation by the Israel

Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our

securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary

in order to commercialize our products, and other factors that are discussed in our in our Annual Report on Form 20-F for the

year ended December 31, 2018 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties

under Risk Factors' in our Registration Statements and Annual Reports. These are factors that we believe could cause

our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely

affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention

or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a

result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult

any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.gov.

For further information, contact:

Deputy CEO & Chief Financial Officer

+972-3-933-3121 ext. #105

Darren Opland, Ph.D.